The new biopic offered the actress a chance to alter her star persona and portray a harrowing story of survival, in and out ...

If you’re a gun owner, what can you do with your firearms while you head out on a long deployment or PCS? Pause to Protect ...

More than 800,000 people in the past 25 years have lost their lives to gun violence in the United States. Another 2 million or more have been injured. A Washington University researcher and a new ...

For its time and place, the Colt Single Action Army was the total package – powerful, rugged, and so well-shaped that it felt ...

In response to a recent increase in violence toward first responders, the Kansas City Fire Department is sending all of its ...

** When you buy products through the links on our site, we may earn a commission that supports NRA's mission to protect, preserve and defend the Second Amendment. ** Charter Arms, manufacturers of 100 ...

But Sue thought Noel's idea was "bonkers" AFTER “bratty” behaviour from the kids turned a luxe family holiday to Florida sour, Noel Radford decided he had to act. But instead of grounding the Radford ...

The likelihood of survival is less than 100 percent, for sure. But how much less? First, let’s go back in time, to the Pac-12’s multi-year existential crisis, for important context on the Hotline’s ...

It’s day 22 of life at sea, and we’re relying on the ocean to feed us. In this video, we head out spearfishing in search of dinner, sharing the challenges, close calls, and rewards that come with ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Between 2014 and 2023, increases in active treatment and survival among infants born between 22 and 25 weeks' gestation were most pronounced at 22 weeks, according to a retrospective cohort study.

Akeso has shared for the first time overall survival data from a high-profile Keytruda head-to-head trial for its PD-1xVEGF bispecific ivonescimab—and investors in the company's partner Summit ...